Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 2/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | SCN1A | P35498 | 1/20 | 0.47 |
| ▸ | SCN4A | P35499 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15966185 | 0.87 | BACE1 (0.50) | TSHRCYP2C19POLBTDP1LMNA | |
| SCHEMBL20290106 | 0.86 | TSHR (0.47) | TSHRCYP2C19POLBTDP1FAAH | |
| SCHEMBL7531542 | 0.83 | POLB (0.46) | TSHRCYP2C19POLBTDP1LMNA | |
| SCHEMBL29763558 | 0.83 | FAAH (0.58) | TSHRCYP2C19POLBTDP1HRH1 | |
| SCHEMBL4439923 | 0.82 | CNR1 (0.46) | TSHRCYP2C19POLBTDP1LMNA | |
| SCHEMBL4436971 | 0.82 | CNR1 (0.46) | TSHRCYP2C19POLBTDP1LMNA | |
| SCHEMBL11885823 | 0.77 | TDP1 (0.63) | POLBTDP1HRH1HRH3SIGMAR1 | |
| SCHEMBL11885815 | 0.77 | POLB (0.63) | POLBTDP1HRH1FAAHHRH3 | |
| SCHEMBL7533808 | 0.77 | POLB (0.41) | TSHRCYP2C19POLBTDP1LMNA | |
| SCHEMBL1461591 | 0.76 | TDP1 (0.54) | POLBTDP1HRH1HRH3CACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0900227-B1 | IMPROVED PROCESS FOR THE SYNTHESIS OF DIESTERS OF PHOSPHORIC ACID 2,5-DIOXO-4,4-DIPHENYL-IMIDAZOLIDIN-1-YLMETHYL ESTER | WARNER LAMBERT CO (US) | 2001-12-12 | — | — | EP | claimed |
| EP-0680469-B1 | AMINOACID DERIVATES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND PROCESS FOR PREPARING THE SAME | BOEHRINGER INGELHEIM PHARMA (DE) | 2000-04-26 | — | — | EP | claimed |
| EP-0040224-A4 | AN IMPROVED METHOD OF NON HOMOGENOUS ENZYME IMMUNOASSAY. | PRINCE CHARLES HOSPITAL DEV CT (AU) | 1982-09-09 | — | — | EP | claimed |
| EP-0040224-A1 | AN IMPROVED METHOD OF NON HOMOGENOUS ENZYME IMMUNOASSAY | THE PRINCE CHARLES HOSPITAL DEVELOPMENT CENTRE TRUST (AU) | 1981-11-25 | — | — | EP | claimed |
| WO-1981001414-A1 | AN IMPROVED METHOD OF NON HOMOGENOUS ENZYME IMMUNOASSAY | CHARLES HOSPITAL DEV (AU) | 1981-05-28 | — | — | WO | claimed |
| US-12565499-B2 | Compounds and methods | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| US-20240208974-A1 | NOVEL COMPOUNDS AND METHODS | INTRA-CELLULAR THERAPIES, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-11958852-B2 | Compounds and methods | INTRA-CELLULAR THERAPIES, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230279048-A1 | COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION | 2023-09-07 | — | — | US | disclosed |
| EP-3772362-B1 | DEVICE FOR MAGNETIC FIELD STIMULATION OF BODY TISSUE OF A USER FOR USE IN DIGITAL TELEMEDICINE, IN PARTICULAR ACCORDING TO THE E-PULS METHOD FOR PELVIC FLOOR OPTIMISATION | PROF DR FISCHER AG (LI) | 2022-12-21 | — | — | EP | disclosed |
| US-11518782-B2 | Compositions containing HC-HA/PTX3 complexes and methods of use thereof | TISSUETECH, INC. (US) | 2022-12-06 | — | — | US | disclosed |
| US-11439675-B2 | Method for treating damage induced by sleep deprivation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-09-13 | — | — | US | disclosed |
| WO-2009017259-A1 | A MEDICAMENT FOR TREATING GLAUCOMA COMPRISING AS AN ACTIVE INGREDIENT CYCLODEXTRIN-CLATHRATE COMPOUND OF CILOSTAZOL | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-02-05 | — | — | WO | disclosed |
| US-20040223983-A1 | Pharmaceutical preparations, use of these preparations and process for increasing the biovailability of pharmaceutical substances to be administered perorally | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-11-11 | — | — | US | disclosed |
| US-5807875-A | OBESITY THERAPY | DR. KARL THOMAE GMBH (DE) | 1998-09-15 | — | — | US | disclosed |
| US-5616620-A | HYPOTENSIVE AGENTS | KARL THOMAE GMBH (DE) | 1997-04-01 | — | — | US | disclosed |
| EP-0040224-A4 | AN IMPROVED METHOD OF NON HOMOGENOUS ENZYME IMMUNOASSAY. | PRINCE CHARLES HOSPITAL DEV CT (AU) | 1982-09-09 | — | — | EP | disclosed |
| US-4348204-A | COTTON, REGENERATED CELLULOSE, PAPER; TETRAKISAZO DYES | CASSELLA AKTIENGESELLSCHAFT (DE) | 1982-09-07 | — | — | US | disclosed |
| EP-0040224-A1 | AN IMPROVED METHOD OF NON HOMOGENOUS ENZYME IMMUNOASSAY | THE PRINCE CHARLES HOSPITAL DEVELOPMENT CENTRE TRUST (AU) | 1981-11-25 | — | — | EP | disclosed |
| WO-1981001414-A1 | AN IMPROVED METHOD OF NON HOMOGENOUS ENZYME IMMUNOASSAY | CHARLES HOSPITAL DEV (AU) | 1981-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12565499-B2 | Compounds and methods | PSEN1, CHAT, SNCA | TSHR 1412/4885CYP2C19 308/4885POLB 1426/4885 |
| US-11439675-B2 | Method for treating damage induced by sleep deprivation | SI, CRY2, PER2 | TSHR 4551/4885CYP2C19 1909/4885POLB 689/4885 |
| US-20240208974-A1 | NOVEL COMPOUNDS AND METHODS | GRIN2C, CHAT, CHRNA5 | TSHR 2185/4885CYP2C19 314/4885POLB 1010/4885 |
| US-11958852-B2 | Compounds and methods | GRIN2C, HTR2C, CHAT | TSHR 2513/4885CYP2C19 229/4885POLB 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.